Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's
sarcoma patients who have no remaining treatment options other than DOX-SL or patients who
have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is
medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with
Kaposi's sarcoma who have previously received systemic chemotherapy with or without an
anthracycline.